1. Fractionated Stereotactic Sequential Boost in a Selected Cohort of Glioblastoma Patients: A Mono-institutional Analysis
- Author
-
Cynthia Aristei, Isabella Palumbo, Marco Lupattelli, Giampaolo Montesi, Vittorio Bini, Stefano Saccia, Nunzia Cenci, Alessandro Marchionni, Pietro Chiarini, and C. Zucchetti
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Survival ,Kaplan-Meier Estimate ,Radiosurgery ,Boost ,Fractionated stereotactic radiotherapy ,Glioblastoma ,Toxicity ,Stereotactic radiotherapy ,Cohort Studies ,Internal medicine ,medicine ,Overall survival ,Humans ,Survival analysis ,Aged ,Proportional Hazards Models ,business.industry ,Brain Neoplasms ,Radiotherapy Planning, Computer-Assisted ,General Medicine ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Treatment Outcome ,Cohort ,Female ,Dose Fractionation, Radiation ,business ,Tomography, X-Ray Computed ,Radiotherapy, Image-Guided - Abstract
Aim To retrospectively assess toxicity and survival in 15 selected Glioblastoma patients treated with a sequential fractionated stereotactic radiotherapy (FSRT) boost after chemo-radiotherapy (CHT-RT) and compare their survival outcomes with a control group. Patients and methods Toxicity was assessed with the CTCAE 3.0 scale. The Kaplan-Meier method was used to design survival curves, log-rank test for bivariate analysis and Cox proportional hazard regression model for multivariate analysis. Results The median follow-up was 16 months (range=5-60). One case of headache and one of radionecrosis (RN) occurred. Median overall survival (OS) was 25 months in the boost group vs. 14 in the no-boost group (p=0.004). Median progression-free survival (PFS) was 15 months in the boost group versus 8 in the no-boost group (p=0.046). At multivariate analysis FSRT boost resulted significantly associated with OS and PFS. Conclusion In our series a sequential FSRT boost resulted in safe outcomes and significantly associated with survival.
- Published
- 2020